The impact of insight in a first-episode mania with psychosis population on outcome at 18 months

J Affect Disord. 2014:167:74-9. doi: 10.1016/j.jad.2014.05.055. Epub 2014 Jun 2.

Abstract

Background: To explore whether poor initial insight during a first episode of mania with psychotic features was predictive of poor psychosocial and clinical outcomes at 18 months.

Methods: Secondary analysis was performed on data collected during an 8-week RCT comparing the efficacy of olanzapine versus chlorpromazine as an adjunct to lithium, and at 18-month follow-up. 74 participants were divided into three groups (no insight, partial insight, and full insight) according to the insight item from the Young Mania Rating Scale (YMRS). Differences between these three groups were examined at baseline and at 18 months on measures of symptoms (YMRS, HAMD-21, and CGI-S), and social and occupational functioning (SOFAS). Baseline differences between the three groups were determined using general linear models and chi-squared analyses. Group differences from baseline to 18-month follow-up were determined using repeated measures general linear models.

Results: At baseline there were significant differences between the three insight groups in terms of mania and functioning, but at 18 months all groups had improved significantly in terms of psychopathology, mania, depression and social and occupational functioning. There were no significant differences between the three groups at study completion with respect to these domains.

Limitations: The study was limited by the lack of availability of a more detailed rating scale for insight, and it did not account for the duration of untreated psychosis (DUI).

Conclusions: Poor initial insight during a first episode of mania with psychotic features does not predict poor clinical and psychosocial outcome at 18 months.

Keywords: Bipolar disorder; First-episode; Insight; Mania; Prognosis.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents / therapeutic use*
  • Awareness*
  • Benzodiazepines / administration & dosage
  • Bipolar Disorder / complications
  • Bipolar Disorder / drug therapy*
  • Bipolar Disorder / psychology*
  • Chi-Square Distribution
  • Chlorpromazine / administration & dosage
  • Depression / complications
  • Depression / psychology
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Judgment*
  • Linear Models
  • Lithium Compounds / administration & dosage
  • Male
  • Middle Aged
  • Olanzapine
  • Predictive Value of Tests
  • Prognosis
  • Psychotic Disorders / complications
  • Psychotic Disorders / psychology*
  • Severity of Illness Index
  • Social Adjustment

Substances

  • Antipsychotic Agents
  • Lithium Compounds
  • Benzodiazepines
  • Olanzapine
  • Chlorpromazine